+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Survival in Parkinson's disease in relation to striatal dopamine transporter binding

Survival in Parkinson's disease in relation to striatal dopamine transporter binding

Parkinsonism and Related Disorders 42: 66-72

To investigate whether dopamine transporter (DAT) binding, as measured with single photon emission computed tomography (SPECT), can be used to predict mortality in patients with Parkinson's disease (PD). A total of 162 patients with PD and abnormal [I-123]FP-CIT SPECT were clinically followed for a median of 5.8 years. A multivariate Cox regression model was used to investigate survival with the independent predictors of age, gender, severity of motor impairment, levodopa-equivalent daily dose of medication, presence of cognitive defects, and putaminal specific binding ratio (SBR) of [I-123]FP-CIT. In addition, associations between striatal and extrastriatal SBRs and survival were investigated using voxel-based analyses. The overall mortality was 25.9%, and the Kaplan-Meier estimate for mortality was 36%. Older age (P < 0.001), presence of cognitive defects (P = 0.001), and more severe motor symptom severity (P = 0.002) were significantly associated with increased mortality. No associations were found between putaminal DAT binding and survival (P = 0.99). There were no significant differences in SBRs in any striatal or extrastriatal region between survivors and non-survivors, and no associations were found between SBRs and scan-to-death intervals among non-survivors. Unlike the severity of motor and cognitive symptoms, the level of striatal dopaminergic defect in DAT SPECT does not predict mortality in PD. Although presynaptic dopaminergic functional imaging may have value as a diagnostic tool, the clinical symptom-based characteristics are superior for predicting lifespan.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 060302539

Download citation: RISBibTeXText

PMID: 28662820

DOI: 10.1016/j.parkreldis.2017.06.013

Related references

Lower 123 I-FP-CIT binding to the striatal dopamine transporter, but not to the extrastriatal serotonin transporter, in Parkinson's disease compared with dementia with Lewy bodies. Neuroimage. Clinical 19: 130-136, 2018

Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation. Movement Disorders 21(8): 1144-1147, 2006

Periodic leg movements in patients with Parkinson's disease are associated with reduced striatal dopamine transporter binding. Journal of Neurology 250(1): 83-86, 2003

Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years. Nuclear Medicine Communications 22(6): 721-725, 2001

Striatal dopamine transporter binding in patients with Parkinson's disease and severe occupational hydrocarbon exposure. European Journal of Neurology 14(3): 297-299, 2007

123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neurological Sciences 24(3): 149-150, 2003

Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis. Archives of Neurology 57(2): 205-208, 2000

Striatal Dopamine transporter in Parkinson's disease: A Study With a New Radioligand, [(123)I]B-CIT-FP. Parkinsonism and Related Disorders 3(2): 77-81, 1997

Dopamine-transporter levels drive striatal responses to apomorphine in Parkinson's disease. Brain and Behavior 3(3): 249-262, 2013

Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's disease. European Journal of Nuclear Medicine 28(10): 1523-1528, 2001

Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology 62(9): 1568-1572, 2004

Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels. Journal of Neurology Neurosurgery and Psychiatry 85(2): 148-152, 2014

Striatal dopamine transporter in different disability stages of Parkinson's disease studied with [(123)I]beta-CIT SPECT. Parkinsonism and Related Disorders 1(1): 47-51, 1995

Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. Journal of Nuclear Medicine 46(2): 227-232, 2005

Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients. Parkinsonism and Related Disorders 21(5): 489-493, 2015